Equity Overview
Price & Market Data
Price: $2.20
Daily Change: $0.00 / 0.00%
Daily Range: $2.20 - $2.20
Market Cap: $818,967,711
Daily Volume: 5,000
Performance Metrics
1 Week: 0.96%
1 Month: -9.09%
3 Months: -12.00%
6 Months: -37.14%
1 Year: 161.4%
YTD: -8.33%
Details
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.